Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AF for each…

Clarivate Epidemiology’s coverage of Crohn’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of acute coronary syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…

Our forecasts are made on the basis of changing levels of exposure to known risk or protective factors rather than extrapolation of historical trends. Factors are included in our forecast model…

DRG Epidemiology’s coverage of myelodysplastic syndromes comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of hospital treated (HT) gram-negative infections (GNIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

DRG Epidemiology’s coverage of minor depression comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of minor depression for each…

Methicillin-Resistant Staphylococcus aureus Epidemiology AbstractDRG Epidemiology’s coverage of methicillin-resistant staphylococcus aureus comprises epidemiological estimates of key patient…

Clarivate Epidemiology’s coverage of hospital treated (HT) gram-positive infections (GPIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

Last Updated 15 October 2015 The type 2 diabetes therapy market will rapidly expand over our 2014-2024 study period, fueled by the disease’s increasing prevalence and a high unmet need for…

In This Increasingly Crowded Setting, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? Treatment decisions for non-small-cell lung cancer (NSCLC)…

What Improvements Do Physicians and Payers Expect from Emerging Therapies? Owing to a lack of specific symptoms, the majority of patients with ovarian cancer (CaO) present at an advanced stage…